To what extent can the pharmaceutical industry police itself?
The question arises in light of a recent episode in which Astellas ran afoul of industry standards in the U.K. Yet the trade group overseeing a much-touted voluntary code declined to take any action — even though the company, until last June, was suspended from the group for egregious practices and an appeals board recommended expelling the drug maker from the organization.
About the Author Reprints
